GSK unveils Keytruda head-to-head data in lung cancer—and they look good at first glance

GSK’s emerging oncology business just got a much-needed boost after several recent setbacks.

After GSK last month said its PD-1 inhibitor Jemperli matched up to Merck & Co.’s Keytruda at shrinking non-small cell lung cancer (NSCLC) in a phase 2 trial, the company now has more information to share. And the data look solid—at least at first glance.